4512-49-6

Usage

Molecular structure

2-(((benzyloxy)carbonyl)amino)-2-methylbutanoic acid consists of a 2-methylbutanoic acid backbone, an amino group, and a benzyloxy carbonyl group.

Benzyloxy carbonyl group

Also known as a benzyl ester, it contains a benzene ring attached to a carbonyl group (C=O).

Amino group

Contains a nitrogen atom (N) bonded to the carbon atom of the carbonyl group.

Potential applications

The compound may have potential applications in the field of organic synthesis and pharmaceuticals.

Unique structure

The combination of the 2-methylbutanoic acid backbone, amino group, and benzyloxy carbonyl group gives the compound a unique structure.

Functional groups

The presence of the amino group and benzyloxy carbonyl group provides the compound with various functional properties, which can be utilized in chemical reactions and pharmaceutical development.

Upstream product

• 501-53-1 benzyl chloroformate 
• 72408-58-3 2-amino-2-methylbutyric acid hydrochloride 
• 595-39-1 DL-isovaline 

Downstream Products

• 5105-46-4 Z-DL-α-Ethylalanin-tert.-butylester 
• 1431141-04-6 C₁₉H₁₉F₂N₃O₅S 
• 1431141-03-5 C₁₉H₂₁N₃O₅S 
• 1431141-02-4 C₁₉H₁₈F₃N₃O₄S 
• 1431141-01-3 C₁₈H₁₈ClN₃O₄S 
• 1431141-00-2 C₁₈H₁₈ClN₃O₄S 
• 1431141-26-2 C₁₂H₁₆N₂O₃ 
• 1431140-99-6 C₁₈H₁₈ClN₃O₄S 
• 1431141-25-1 C₂₀H₂₂N₂O₅ 
• 1444224-07-0 C₁₃H₁₆FNO₃ 
• 1431140-98-5 C₁₈H₂₅N₃O₄S 
• 1431140-97-4 C₁₉H₂₁N₃O₄S 
• 1431141-12-6 C₁₉H₂₁N₃O₄S 
• 1431141-21-7 C₁₈H₁₇F₂N₃O₄S 

Relevant academic research and scientific papers

PYRAZOLE DERIVATIVES AS SGC STIMULATORS

There are described imidazole and pyrazole derivatives which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.

Identification and design of a novel series of MGAT2 inhibitors

[Acyl CoA]monoacylglycerol acyltransferase 2 (MGAT2) is of interest as a target for therapeutic treatment of diabetes, obesity and other diseases which together constitute the metabolic syndrome. In this Letter we report our discovery and optimisation of a novel series of MGAT2 inhibitors. The development of the SAR of the series and a detailed discussion around some key parameters monitored and addressed during the lead generation phase will be given. The in vivo results from an oral lipid tolerance test (OLTT) using the MGAT2 inhibitor (S)-10, shows a significant reduction (68% inhibition relative to nave, p 0.01) in plasma triacylglycerol (TAG) concentration.